Navigation Links
Cantel Medical Reports 75% Increase in Net Income - EPS of $0.23 vs. $0.13 for Quarter Ended January 31, 2009

LITTLE FALLS, N.J., March 9 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 75% increase in net income to $3,774,000, or $0.23 per diluted share, on a 2.5% increase in sales to $62,420,000 for the second quarter ended January 31, 2009. This compares with net income of $2,157,000, or $0.13 per diluted share, on sales of $60,910,000 for the second quarter ended January 31, 2008. For the six months ended January 31, 2009, the Company reported a 74% increase in net income to $7,107,000, or $0.43 per diluted share (inclusive of $0.02 of expenses related to the relocation of its Dutch manufacturing operations to the United States), on a 5% increase in sales to $126,826,000. This compares with net income of $4,096,000, or $0.25 per diluted share, on sales of $120,915,000 for the six months ended January 31, 2008.

Andrew Krakauer, Cantel's President stated, "We are very pleased to have delivered another quarter of substantial earnings growth and our strongest quarterly performance of the past few years. These positive results confirm the continued success of our sales and marketing investments and various initiatives to improve operating margins. Cantel demonstrated sales growth in all reporting segments except for Water Purification and Filtration which was affected by some delayed capital sales and an unusually favorable comparative quarter in the prior year."

Krakauer added, "While all our businesses performed well, operating income in our Endoscope Reprocessing and Dialysis units was substantially ahead of last year, aided by strong sales of consumables, including disinfectants, sterilants and an increase in service revenue. Additionally, the positive performance was helped by our active cost reduction and margin improvement programs, the implementation of price increases and reduced interest expenses."

Krakauer continued, "Although our businesses are not immune to the economic downturn, we remain focused on our strategies to grow and improve performance. In this economy, our competitive advantage is our leadership positions in several infection prevention and control markets, a quality reputation and strong brands. Further, we have proactively developed our business to where approximately 70% of our sales come from disposables and service, which are supported by a large installed base of equipment."

The Company further reported that its balance sheet at January 31, 2009 included current assets of $85,728,000, including cash of $20,052,000, a current ratio of 2.4:1, debt of $54,300,000, stockholders' equity of $171,838,000 and a ratio of funded debt to equity of .32:1. Krakauer stated, "The Company has a strong balance sheet and continues to generate significant cash. Our cash provided by operating activities for the quarter was $7,801,000. We have reduced our net debt position from the first quarter by 18% to $34.2 million, which is less than one (1x) turn of our trailing EBITDAS."

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.

The Company will hold a conference call to discuss the results for the second quarter ended January 31, 2009 on Monday, March 9, 2009 at 11:00 AM Eastern time. To participate in the conference call, dial 1-877-407-8035 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Monday, March 9 at 2:00 PM through midnight on March 10, by dialing 1-877-660-6853 and using passcode #286 and conference ID #315449.

The call will be simultaneously broadcast live over the Internet on at A replay of the webcast will be available on Vcall for 30 days.

For further information, visit the Cantel website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

                           CANTEL MEDICAL CORP.
                   (In thousands, except per share data)

                                Three Months Ended   Six Months Ended
                                    January 31,        January 31,
                                    -----------        -----------
                                   2009     2008      2009      2008
                                   ----     ----      ----      ----

    Net sales                    $62,420  $60,910  $126,826  $120,915

    Cost of sales                 38,809   39,424    79,592    78,223
                                  ------   ------    ------    ------

    Gross profit                  23,611   21,486    47,234    42,692

      Selling                      6,992    6,836    14,342    13,625
      General and administrative   9,037    8,967    18,061    17,924
      Research and development       983      961     2,048     1,951
                                  ------   ------    ------    ------
    Total operating expenses      17,012   16,764    34,451    33,500
                                  ------   ------    ------    ------

    Income before interest
     and income taxes              6,599    4,722    12,783     9,192

    Interest expense                 674    1,255     1,425     2,477
    Interest income                  (38)    (150)     (108)     (297)
                                  ------   ------    ------    ------

    Income before
     income taxes                  5,963    3,617    11,466     7,012

    Income taxes                   2,189    1,460     4,359     2,916
                                  ------   ------    ------    ------

    Net income                    $3,774   $2,157    $7,107    $4,096
                                  ======   ======    ======    ======

    Earnings per common
     share - diluted               $0.23    $0.13     $0.43     $0.25
                                  ======   ======    ======    ======

    Weighted average
     shares - diluted             16,415   16,386    16,382    16,359

                           CANTEL MEDICAL CORP.
                             (In thousands)

                                     January 31,    July 31,
                                         2009         2008
                                         ----         ----
    Current assets                    $85,728      $84,561
    Property and equipment, net        36,248       37,920
    Intangible assets                  37,972       41,254
    Goodwill                          111,860      113,958
    Other assets                        1,084        1,497
                                      -------      -------
                                     $272,892     $279,190
                                     ========     ========

      Liabilities and stockholders'
    Current portion of long-term
     debt                              $9,000       $8,000
    Other current liabilities          27,438       30,922
    Long-term debt                     45,300       50,300
    Other long-term liabilities        19,316       21,256
    Stockholders' equity              171,838      168,712
                                      -------      -------
                                     $272,892     $279,190
                                     ========     ========


    Reconciliation of Earnings Before Interest, Taxes, Depreciation,
     Amortization and Stock-Based Compensation Expense ("EBITDAS")

    The reconciliation of EBITDAS with net income for the three and six
     months ended January 31, 2009 and 2008, respectively, is as follows
     (in thousands):

                                         Three Months Ended  Six Months Ended
                                              January 31,      January 31,
                                              -----------      -----------
                                             2009    2008     2009     2008
                                             ----    ----     ----     ----

    Net income                              $3,774  $2,157   $7,107   $4,096

    Income taxes                             2,189   1,460    4,359    2,916
    Interest expense                           674   1,255    1,425    2,477
    Interest income                            (38)   (150)    (108)    (297)
    Depreciation                             1,525   1,530    3,075    2,975
    Amortization                             1,268   1,460    2,606    2,859
    Loss on disposal of fixed assets             8      49       22       49
                                            ------  ------   ------   ------

    EBITDA                                   9,400   7,761   18,486   15,075

    Stock-based compensation expense           525     462    1,045      994
                                            ------  ------   ------   ------
    EBITDAS                                 $9,925  $8,223  $19,531  $16,069
                                            ======  ======  =======  =======

EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with, Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by the Company as income before interest, taxes, depreciation, amortization and stock-based compensation expense. The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historically resulted in significant increases in amortization of intangible assets that reduced the Company's net income. Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and complements operating income, net income and other GAAP financial performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

SOURCE Cantel Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its Second Quarter Ended January 31, 2009
2. Cantel Medical Corp.s Medivators Group Gains FDA 510(k) Approval For Its Advantage(TM) Plus Endoscope Reprocessing System
3. Cantel Medical Corp. to Present at the 11th Annual Needham Growth Stock Conference
4. Cantel Medical Reports 72% Increase in Net Income on Record Sales - EPS of $0.20 vs. $0.12 for Quarter Ended October 31, 2008
5. Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008
6. Cantel Medical Corp. to Present at the Oppenheimer & Co. 19th Annual Healthcare Conference
7. Cantel Medical to Relocate Dutch Manufacturing Operations to the United States to Achieve Operating Savings
8. Cantel Medical Corp. and National Safety Council Launch Joint Initiative to Prepare Businesses and Individuals for Flu Pandemic
9. Response Biomedical Named Medical Device Company of the Year by LifeSciences British Columbia
10. EORNA Launches First European Accreditation System for Continuous Medical Education of Nursing and Healthcare Professionals
11. $12 Million New Jersey Medical Malpractice Verdict for Wrongful Death of a 21-Year-Old Man After Having Wisdom Teeth Removed
Post Your Comments:
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition ... has initiated a second print-run of its lavish luxury travel coffee table book. ... weighs in at more than six kilos, retails at EUR 1,000 per copy and ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Smart Machine Age is ... University predict that 47 percent of all jobs in the United States may be ... “successful.” The day of the aggressive know-it-all who steamrolls over colleagues is drawing to ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: An Australian ... account of his paramedic experiences. Schanssema describes the tragedies he saw, as well as ... overcome them. , Schanssema, initially unsure of the career path he wanted to take, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
Breaking Medicine Technology: